<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01703455</url>
  </required_header>
  <id_info>
    <org_study_id>INT29/10</org_study_id>
    <nct_id>NCT01703455</nct_id>
  </id_info>
  <brief_title>Activity of Sorafenib in Salivary Gland Cancer</brief_title>
  <official_title>Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single agent, prospective, open-label, monocenter, phase II trial of sorafenib in
      patients with recurrent and/or metastatic salivary gland carcinoma. This trial will be
      conducted with the primary aim to determine the response rate (CR+PR) according to the RECIST
      criteria. Response rate according to CHOI criteria, correlation between CHOI criteria and
      outcome, disease Control Rate (DCR) and acute toxicity will be evaluated as secondary
      objectives.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Response Rate according to RECIST criteria. Response will be evaluated every 2 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate according to CHOI criteria</measure>
    <time_frame>8 weeks</time_frame>
    <description>assessment of tumor response according to CHOI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between CHOI criteria and outcome</measure>
    <time_frame>one year</time_frame>
    <description>correlation between CHOI criteria and survival (OS and PFS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>number of patients with adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Salivary Gland Cancer</condition>
  <arm_group>
    <arm_group_label>Sorafenib 400 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles</description>
    <arm_group_label>Sorafenib 400 mg twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven relapsed and/or metastatic salivary gland cancer for which
             potentially curative options such as surgery or radiotherapy are not indicated

          -  One target lesion measurable by CT-scan or MRI according to RECIST criteria

          -  Age + 18 years

          -  ECOG 0 or 1

          -  Adequate bone marrow, liver and renal function

          -  Signed written informed consent

        Exclusion Criteria:

          -  Symptomatic metastatic brain or meningeal tumors

          -  History of cardiac disease such as congestive heart failure&gt;NYHA class 2

          -  Active CAD

          -  Cardiac arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension

          -  Pregnant or breast-feeding patient

          -  Patients with evidence or history of bleeding diathesis

          -  Patients undergoing renal dialysis

          -  Patients unable to swallow oral medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>October 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Lisa Licitra</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Salivary gland cancer metastatic disease recurrent disease clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

